Plus Therapeutics (PSTV) said Wednesday that the US Food and Drug Administration has cleared its investigational new drug application for Reyobiq, paving the way for a phase 1/2a trial targeting pediatric patients with recurrent or progressive high-grade glioma and ependymoma.
The company said the trial, which will assess safety, maximum tolerated dose, and preliminary efficacy in patients aged 6 to 21, will be funded by a $3 million grant from the US Department of Defense.
The phase 1 portion will enroll 24 patients using a dose-escalation approach, while phase 2 will evaluate efficacy in an additional 32 patients, it said.
Shares of the company were rising more than 103% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。